Category Archives: Transhuman News

Tulsa, OK, Oct. 26, 2021 (GLOBE NEWSWIRE) -- viaNewMediaWire --AppSwarm, Corp. (OTC:SWRM), a software development company and aggregator of mobile applications, announced it has begun beta testing its own brand of consumer smartwatches for the wearable health and longevity market.

The Company is pleased to announce it has begun beta testing on its own brand of smartwatch devices that will provide health data to users, and open the door to customized add-on subscription cloud services.

Our team will begin testing functionality, and mobile SDK for data integration with third-party applications. Upon successful completion, the company will conduct an initial soft launch, with a hopeful goal of the holiday season.

SmartWatch Features

- Activity (steps, calories, distance)- Heart rate- Blood Oxygen- Sleep (total duration, deep sleep, light sleep)- Sports mode (walking, running, cycling, swimming, climbing, etc.)

The Company will utilize data generated from its wearable devices and sensors to develop cloud-based analytics that will monitor and analyze a users health data through long-term dataset development, utilizing artificial intelligence.

Distribution

Along with traditional online retail, the company will also work with its collaboration partner GTX Corp (GTXO) to resell our smartwatch devices where GTX has established channels of distribution.

The Company also plans to integrate its wearable devices with the GTX SmartSole platform to enable the collected biometric data to be sent to a central hub in the cloud without the need for a smartphone.

Chris Bailey, the CEO of AppSwarm, Corp., commented, "Our core mission is to develop technologies and applications for the betterment of mankind. Data has shown technology has had a negative effect on human health, both physical and mental, from the rise of metabolic diseases, depression, and anxiety. But we feel technology, deployed properly, can also be used to refocus human behavior back to a more positive aspect. Our focus on smart devices geared towards human health goes towards our mission to leverage technology that can potentially assist society and expand human longevity."

A more detailed roadmap and timeline of our smart device operations will be released shortly.

About APPSWARM

AppSwarm is a technology company specializing in accelerated development and publishing of mobile apps and other software platforms for gaming and business applications and seeks to acquire symmetric business opportunities. AppSwarm partners with and assists other development firms in technology development, business management, and funding needs.

For more information, visit us atwww.app-swarm.comor follow us onwww.facebook.com/AppSwarmTwitterhttps://twitter.com/AppSwarmor Instagramhttps://www.instagram.com/appswarm/

Forward-Looking Statements:

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release may contain forward-looking statements that are subject to risk and uncertainties including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk, and other risks detailed from time to time in the Company's filings with OTCMarkets.com and as required to the Securities and Exchange Commission. These risks could cause SWRM's actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Company.

Investor and Media Contacts:

AppSwarm, Corp.888-886-8583info@app-swarm.com

Continued here:
AppSwarm Begins Beta Testing Smart Watch Device for Health

Healthy Longevity Initiative Grant Awarded to Study the Mycobiome as a Novel Class of Probiotics to Target Inflammaging

CAMBRIDGE, Mass., Nov. 4, 2021 /PRNewswire/ -- Solarea Bio, a biotechnology company in Cambridge, Mass., and leading researchers at Harvard Medical School affiliated Hebrew SeniorLife, New England's largest nonprofit provider of senior health care and living communities, are co-investigators on a competitive research grant from the U.S. National Academy of Medicine's Healthy Longevity Initiative.

(PRNewsfoto/Solarea Bio)

Solarea Bio, along with Douglas P. Kiel, M.D., M.P.H., Director, Musculoskeletal Research Center, Hinda and Arthur Marcus Institute for Aging Research, and Shivani Sahni, Ph.D., Director, Nutrition Program, Marcus Institute, received the grant.

According to the researchers, "An aging population has led to a significant global increase in age-related diseases including cardiovascular disease, Alzheimer's, and others. At the core of this is chronic low-grade inflammation known as inflammaging, and recent evidence describes the gut microbiome as a key regulator of the inflammaging process through direct impact on immune system development and function."

However, while the impact bacteria have on the immune system and human health is well described, fungi, a major component of the gut microbiome, have been largely overlooked due to multiple factors including fungi's large, complex genomes that require deep sequencing and a hybrid assembly, lack of fungal genome databases for functional gene prediction, and underdeveloped bioinformatic tools to identify fungal metabolites important to human health.

The researchers hypothesize that the "mycobiome" (the collection of fungi that are part of the overall microbiome) could offer a large, untapped reservoir of probiotic fungi with the ability to combat inflammaging. Based on this hypothesis, the team will be working to sequence a subset of a large fungal collection and develop bioinformatic tools to identify fungi with probiotic potential. Lead candidate fungi will be tested using in vitro cell culture systems to identify fungi with anti-inflammatory properties that may then be further tested clinically.

Story continues

About the Healthy Longevity InitiativeThe Healthy Longevity Initiative is designed to kick start innovation to support healthy longevity through a series of monetary awards and prizes. In the tradition of international races to fly across the Atlantic or walk on the moon, the initiative will rally the world's greatest minds to achieve what may at first seem an impossible goal.

About the Hinda and Arthur Marcus Institute for Aging ResearchScientists at the Marcus Institute seek to transform the human experience of aging by conducting research that will ensure a life of health, dignity, and productivity into advanced age. The Marcus Institute carries out rigorous studies that discover the mechanisms of age-related disease and disability; lead to the prevention, treatment, and cure of disease; advance the standard of care for older people; and inform public decision-making.

About Hebrew SeniorLifeHebrew SeniorLife, an affiliate of Harvard Medical School, is a national senior services leader uniquely dedicated to rethinking, researching, and redefining the possibilities of aging. Hebrew SeniorLife cares for more than 3,000 seniors a day across six campuses throughout Greater Boston. Our locations include: Hebrew Rehabilitation Center-Boston and Hebrew Rehabilitation Center-NewBridge in Dedham; NewBridge on the Charles, Dedham; Orchard Cove, Canton; Simon C. Fireman Community, Randolph; Center Communities of Brookline, Brookline; and Jack Satter House, Revere. Founded in 1903, Hebrew SeniorLife also conducts influential research into aging at the Hinda and Arthur Marcus Institute for Aging Research, which has a portfolio of more than $63 million, making it the largest gerontological research facility in the U.S. in a clinical setting. It also trains more than 1,000 geriatric care providers each year. For more information about Hebrew SeniorLife, visit https://www.hebrewseniorlife.org or follow us on our blog, Facebook, Instagram, Twitter, and LinkedIn.

About Solarea BioSolarea Bio is a biotechnology company based in Cambridge, Mass. developing new microbiome-based solutions to some of the world's largest health problems. Solarea was founded in 2017 by a group of scientists and entrepreneurs eager to radically alter our understanding of the human microbiome and utilize its power to improve human health. Solarea's breakthrough came from the combined efforts of the company's co-founders who established a link between the discovery of an untapped source of microorganisms with probiotic potential in healthy foods, and their applications in inflammatory processes including the gut-musculoskeletal axis.

Media Contacts:Margaret BonillaHebrew SeniorLife617-363-8367margaretbonilla@hsl.harvard.edu

Rachel Raymond Solarea Biorraymond@solareabio.com

Logo

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/solarea-bio-teams-up-with-hebrew-seniorlife-investigators-on-a-newly-awarded-us-national-academy-of-medicine-catalyst-grant-301416424.html

SOURCE Solarea Bio

Read more from the original source:
Solarea Bio Teams up with Hebrew SeniorLife Investigators on a Newly Awarded U.S. National Academy of Medicine Catalyst Grant - Yahoo Finance

If ones thirties were a decrepit old age, ancient writers and politicians dont seem to have got the message. In the early 7th Century BC, the Greek poet Hesiod wrote that a man should marry when you are not much less than 30, and not much more. Meanwhile, ancient Romes cursus honorum the sequence of political offices that an ambitious young man would undertake didnt even allow a young man to stand for his first office, that of quaestor, until the age of 30 (under Emperor Augustus, this was later lowered to 25; Augustus himself died at 75). To be consul, you had to be 43 eight years older than the USs minimum age limit of 35 to hold a presidency.

In the 1st Century, Pliny devoted an entire chapter of The Natural History to people who lived longest. Among them he lists the consul M Valerius Corvinos (100 years), Ciceros wife Terentia (103), a woman named Clodia (115 and who had 15 children along the way), and the actress Lucceia who performed on stage at 100 years old.

Then there are tombstone inscriptions and grave epigrams, such as this one for a woman who died in Alexandria in the 3rd Century BC. She was 80 years old, but able to weave a delicate weft with the shrill shuttle, the epigram reads admiringly.

Not, however, that ageing was any easier then than it is now. Nature has, in reality, bestowed no greater blessing on man than the shortness of life, Pliny remarks. The senses become dull, the limbs torpid, the sight, the hearing, the legs, the teeth, and the organs of digestion, all of them die before us He can think of only one person, a musician who lived to 105, who had a pleasantly healthy old age. (Pliny himself reached barely half that; hes thought to have died from volcanic gases during the eruption of Mt Vesuvius, aged 56).

In the ancient world, at least, it seems people certainly were able to live just as long as we do today. But just how common was it?

Age of empires

Back in 1994 a study looked at every man entered into the Oxford Classical Dictionary who lived in ancient Greece or Rome. Their ages of death were compared to men listed in the more recent Chambers Biographical Dictionary.

Of 397 ancients in total, 99 died violently by murder, suicide or in battle. Of the remaining 298, those born before 100BC lived to a median age of 72 years. Those born after 100BC lived to a median age of 66. (The authors speculate that the prevalence of dangerous lead plumbing may have led to this apparent shortening of life).

The median of those who died between 1850 and 1949? Seventy-one years old just one year less than their pre-100BC cohort.

Of course, there were some obvious problems with this sample. One is that it was men-only. Another is that all of the men were illustrious enough to be remembered. All we can really take away from this is that privileged, accomplished men have, on average, lived to about the same age throughout history as long as they werent killed first, that is.

Still, says Scheidel, thats not to be dismissed. It implies there must have been non-famous people, who were much more numerous, who lived even longer, he says.

See the rest here:
Do we really live longer than our ancestors? - BBC Future

Moral Or Ethical Problems Associated With Eating Meat

The third reason, ethical or moral concerns, is very personal and varies considerably among each person who chooses to adopt a vegetarian or vegan diet for such reasons. A secondary question, however, also presents itself. With so many people moving towards vegetarianism or veganism, and evidence showing the health benefits to be found in reducing meat consumption, why is the demand for meat still soaring? Why arent more people moving into a vegetarian or vegan diet? There may be a wide variety of answers to this question but lets address just one for now.

Humans have been eating meat for many thousands of years, and it is essentially part of our culture. Put simply: we like it. Most people around the world enjoy the flavors, smells, and texture of meat. Some visionaries have, however, made a lot of progress in bridging these two contrary positions. Plant-based meat is now significantly tastier. Its also a lot more like real meat. The choices now available are also wider than ever before. Start-ups and major companies alike are now producing vegan steaks, vegan sausages, vegan kabobs, and a multitude of other plant-based meat options.

Some may ask if we really need to mimic the taste of meat? Shouldnt we just try to move towards a vegetarian diet? Different people will come to different answers to this question, but as noted, giving up meat is not quite as easy as it sounds.

The people who create vegan meat understand this problem and are doing their best to produce solutions that can satisfy the cravings many people feel for meat.

View post:
Changing Hearts And Minds With Vegan Meat - Longevity LIVE - Longevity LIVE

Palm Beach, Florida--(Newsfile Corp. - November 3, 2021) - In an effort that will expand the Company's technology leadership, JZZ Technologies, Inc. (OTC Pink: JZZI) has added Michael Wiley in a key position that will advise the board and leadership on acquisitions and the build-out of future technology capabilities.

In his more than 25 years of working in the Technology Industry at tech startups Cisco Systems, JPMorgan, Google, and F5 Networks, Inc. as Application CTO, Mr. Wiley has led many engineering teams, software, and product solutions at a massive scale. His extensive knowledge of cloud, mobile, and advanced applications will be a great addition to JZZ Technologies, Inc. He has also implemented products and engineering strategies for key industries ranging from non-profits, retail, service industries, emerging markets, and the financial sector. His guidance will be instrumental in leading and managing JZZ Technologies' corporate strategies and the ability to employ key technologies for its customers.

"We have been making tremendous progress as a company, and our initiatives have reached a point where we require a skilled and capable professional like Michael Wiley to advise on our technology strategies, capabilities and acquisitions," says Charles Cardona, CEO of JZZ Technologies, Inc.

"Mr. Wiley has an impressive background in building software and engineering organizations at hyper-scale, launching products, and building within many challenging market sectors. He brings a diverse set of talents to the table, along with a fantastic work ethic. His experience will be critical as we expand our digital properties and other ventures, particularly in advancing our technologies, acquisitions and further our market impact. We are fortunate to have Michael Wiley joining JZZ Technologies Inc. to help guide our team," Cardona added.

About JZZ Technologies, Inc.

JZZ Technologies, Inc. is a diversified technology company rolling up projects and partnerships in two distinct business sectors that operate cohesively; its digital media business includes online media and apps (activelifestylemedia.com), content creation, digital marketing, streaming video content, publishing, and free over-the-air television (EyeOnTV) targeted at active adults 55+. The Company's other business is focused on strategic biotechnology and bioscience acquisitions related to Human Life Extension and Human Longevity that can be immediately leveraged to support improved quality of life for aging populations.

DISCLAIMER and FORWARD-LOOKING STATEMENTS

Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities and Exchange Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, and such Forward-Looking Statements are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainties. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to the viability of the company's business plans, the effect of acquisitions on our profitability, the effectiveness, profitability, and the marketability of the Company's products; the Company's ability to protect its proprietary information; general economic and business conditions; the volatility of the company's operating results and financial condition; and other risks detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates, and projections about the company and the industry. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances or to changes in its expectations, except as may be required by law. Although the company believes that the expectations expressed in these forward-looking statements are reasonable, management cannot assure the public that their expectations will turn out to be correct. Investors are cautioned that actual results may differ materially from the anticipated results.

Contact: JZZ Technologies, Inc. Charles Cardona, CEO Email: ccardona@jzztechnologies.com Website: https://www.jzztechnologies.com/

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/101822

Originally posted here:
JZZ Technologies, Inc. Expands Technology Leadership with Addition of Michael Wiley as Board Advisor - Stockhouse

DALLAS (PRWEB) November 05, 2021

Texas-based investor John A. Kuelbs announces his commitment to transformative health initiatives with his investment in Elevian, an emerging biotech company developing medicines that restore youthful regenerative capacity, with the potential to treat and prevent multiple age-related diseases.

Over the past century in America, the average life expectancy has increased from 50 years to 80 years. Given the ever-increasing progress of scientific understanding, I think its quite possible to achieve a lifespan of 100 reasonably healthy years, said Kuelbs. Elevian is one of the top companies working to enhance longevity, with impressive preclinical data demonstrating the ability to therapeutically repair damaged tissues and organs.

The Series A funding round will enable Elevian to submit an investigational new drug application, scale manufacturing and complete Phase 1 clinical trials for its lead indication of stroke recovery the first of many potential applications for its breakthrough drug candidate.We are pleased to have the Kuelbs family as investors in Elevian and John as a business advisor, said Dr. Mark Allen, Co-Founder and CEO of Elevian. His insight and experience building valuable companies across numerous industries provide a valuable perspective to the company.

About ElevianElevian is an emerging biotech company developing medicines that restore youthful regenerative capacity, with the potential to treat and prevent multiple age-related diseases. Elevian's scientific founders, working at the Harvard Department of Stem Cell and Regenerative Biology, discovered that treatment with the circulating factor GDF11 can regenerate the heart, brain, muscle and other tissues. Elevian has acquired exclusive, worldwide rights to Harvard's patent portfolio concerning GDF11. The company is developing new medicines that target the GDF11 pathway. Elevian's lead drug candidate (recombinant human GDF11) has demonstrated efficacy in preclinical models of stroke, obesity, Type 2 diabetes, heart failure, Alzheimer's disease, and many other age-related diseases. The company has also established additional programs focused on the discovery and development of novel proteins, antibodies and small molecule drugs that target the GDF11 pathway. For more information, please visit http://www.elevian.com

Share article on social media or email:

Read more:
Kuelbs Family Office Invests in Biotech Company Elevian, Supporting $40 Million Funding Round - PR Web